NCT06227325View on ClinicalTrials.gov

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Gastric Cancer
Interventions
DRUG

RC48 combined with Sintilimab and XELOX

RC48: 2.5 mg/kg, iv, d1, repeat every 2 weeks; Sintilimab: 200mg, iv, d1, repeat every 3 weeks; XELOX: Oxaliplatin 130mg/m2, iv, d1；Capecitabine1000 mg po, bid, d1-14, repeat every 3 weeks

Trial Locations (1)

Unknown

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT06227325 - Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression | Biotech Hunter | Biotech Hunter